



Revista Portuguesa de Pneumologia

ISSN: 0873-2159

sppneumologia@mail.telepac.pt

Sociedade Portuguesa de Pneumologia
Portugal

Duarte, R.; Carvalho, C.; Pereira, C.; Bettencourt, A.; Carvalho, A.; Villar, M.; Domingos, A.; Barros, H.; Marques, J.A.; Pinho Costa, P.; Mendonça, D.; Martins, B.

HLA class II alleles as markers of tuberculosis susceptibility and resistance

Revista Portuguesa de Pneumologia, vol. 17, núm. 1, enero-febrero, 2011, pp. 15-19

Sociedade Portuguesa de Pneumologia

Lisboa, Portugal

Available in: <http://www.redalyc.org/articulo.oa?id=169722528005>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org

redalyc.org

Scientific Information System

Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal

Non-profit academic project, developed under the open access initiative

Rev Port Pneumol. 2011;17(1):15-19



revista portuguesa de
PNEUMOLOGIA
portuguese journal of pulmonology
www.revportpneumol.org

ARTIGO ORIGINAL

HLA class II alleles as markers of tuberculosis susceptibility and resistance

R. Duarte^{a,b,c,*}, C. Carvalho^{a,d}, C. Pereira^d, A. Bettencourt^d, A. Carvalho^{a,c},
A. Domingos^f, H. Barros^b, J.A. Marques^b, P. Pinho Costa^g, D. Mendonça^h,

^a*Centro de Diagnóstico Pneumológico (CDP) de Vila Nova de Gaia, Vila Nova de Gaia, Portugal*

^b*Faculdade de Medicina, Universidade do Porto, Portugal*

^c*Centro Hospitalar de Vila Nova de Gaia/Espinho, Portugal*

^d*Laboratório de Imunogenética, Instituto de Ciências Biomédicas Abe Salazar (ICBAS), Universidade de Porto, Portugal*

^e*Centro de Diagnóstico Pneumológico (CDP) de Venda Nova, Lisboa, Portugal*

^f*Centro Hospitalar Torres Vedras, Torres Vedras, Portugal*

^g*Laboratório de Imunogenética, Instituto Nacional da Saúde (NSA) Dr. Ricardo Jorge, Porto, Portugal*

^h*Departamento de Estudo de Populações, Instituto de Ciências Biomédicas Abe Salazar (ICBAS), Universidade do Porto, Portugal*

Received June 15, 2009; accepted May 5, 2010

KEYWORDS

HLA;
Tuberculosis;
Susceptibility;
Resistance;
Healthcare workers

Abstract

Background: Not every individual exposed to *Mycobacterium tuberculosis* develops the disease. One host genetic factor, involved in modulating the immune response to the pathogen, in many ethnic groups is the association of human leukocyte antigens (HLA) with tuberculosis (TB).

Objective: To investigate the association between TB, HLA-DRB1 and HLA-DQB1 in a Portuguese population.

Methods: HLA-DRB1 and HLA-DQB1 gene polymorphisms were analyzed in a

PALAVRAS-CHAVE

HLA;
Tuberculose;
Susceptibilidade;
Resistência;
Profissionais de saúde

O papel do HLA classe II na susceptibilidade/resistência à tuberculose

Resumo

Introdução: Nem todos os indivíduos expostos ao *Mycobacterium tuberculosis* desenvolvem a doença. Um dos factores genéticos envolvidos na modulação da resposta imune em diferentes grupos étnicos é a associação entre moléculas HLA (*human leucocyte antigens*). A susceptibilidade à tuberculose (TB).

Objectivo: Investigar a relação entre TB e os alelos HLA-DRB1, DQB1 num grupo de indivíduos.

Métodos: Os polimorfismos dos genes HLA-DRB1 e HLA-DQB1 foram analisados em 92 doentes com TB e 82 profissionais de saúde saudáveis, expostos a *M. tuberculosis* bacilíferos por um período superior a 2 anos (expostos saudáveis: ES). No grupo de doentes com TB, o teste tuberculínico foi positivo (TST ≥ 10 mm) em 69 indivíduos (todos com ES+) e negativo (TST < 10 mm) em 13 (ES-). Resultados: A frequência de alelos HLA-DRB1 foi superior no grupo de doentes com tuberculose em relação ao grupo de profissionais de saúde. Conclusões: Não foi identificado neste estudo, nenhum marcador genético associado à resistência à doença. No entanto, o alelo HLA-DRB1*14 foi mais frequente em doentes com tuberculose, sugerindo que possa estar envolvido na evolução da infecção. activa na nossa população.

© 2009 Publicado por Elsevier España, S.L. em nome da Sociedade Portuguesa de Imunologia. Todos os direitos reservados.

Introduction

Infection with *Mycobacterium tuberculosis* (MT) results in a variety of conditions ranging from asymptomatic infection to active tuberculosis (TB) with pulmonary or extrapulmonary involvement. In extreme cases MT infection may be fatal. One third of the World's population is infected with MT;¹ however, only a minority ever develop clinical disease. In 90% of infected individuals, bacilli remain under control in a latent state² (latent TB infection).

The various clinical features of TB result from cell-cell interactions that are promoted by cytokines produced by immune cells in response to MT infection. Studies of the diverse consequences of infection in twins³ and under similar exposure conditions in a familial context⁴ suggest the importance of genetics in susceptibility and/or resistance to TB. Several case-control studies have identified associations between TB disease and gene polymorphisms. Among the candidate genes potentially involved in the immune response to TB are the murine natural resistance-associated macrophage protein 1 (NRAMP1) gene,⁵ the vitamin D

Some hospitals were once TB sanatoria and for many years maintained an important tradition of TB treatment. Until recently, there were no measures to prevent against nosocomial transmission. Isolation rooms have only become common in the last decade. However, after having worked in a setting with high TB exposure and with a long stay during the sanatorium phase, most individuals remained uninfected.

The aim of this study was to evaluate the association with outcome of TB exposure, particularly among professionals heavily exposed to TB, on the importance of HLA-DRB1 and HLA-DQB1

Methods

Subjects

All individuals were vaccinated with bacillus Calmette-Guérin (BCG) at birth, according to the national

HLA class II alleles as markers of tuberculosis susceptibility and resistance

measures against nosocomial TB) for more than two years prior to 2000 were recruited (healthy exposed - HE). All were asymptomatic and presented normal pulmonary radiographies. Based on the results of tuberculin skin test (TST), 69 were found positive (HE+) and thirteen negative (HE−). HE+ positive results ranged from 15 to 20 mm.

Inclusion and exclusion criteria

Individuals belonging to any high-risk groups (e.g., drug users, sex workers, homeless) and persons with co-morbidities that would interfere with TST results or increased risk for TB, such as those with immunosuppressive disease (e.g., HIV infection, rheumatoid arthritis or cancer) or taking any immunosuppressive drug (e.g. corticosteroid) were excluded from the study.

Tuberculin skin test

Trained nursing staff from CDC administered TSTs (2-TU dose of purified protein derivative RT23) according to the guidelines established by the Portuguese Pneumologic Society (SPP).²⁵ Briefly, 0.1 ml of the tuberculin purified protein derivative containing five tuberculin units was injected intradermally on the volar surface of individuals' forearms. After 72 h, the diameter of the indurated area surrounding the injection site was measured and reported in millimeters. We considered 10 mm as the positive cut-off value.

HLA genotyping

Peripheral blood samples (10 ml) were collected in EDTA tubes. Genomic DNA was obtained from Proteinase-K treated peripheral blood leukocytes using a salting-out procedure.²⁶

DNA was amplified by polymerase chain reaction (PCR) using sequence-specific primers (PCR-SSP) for HLA-DRB1 and HLA-DQB1 genes, based on methods previously described.²⁷

PCR products were electrophoresed on 1.5% agarose gels containing ethidium bromide, and visualized under ultraviolet light.

Statistical analysis

HLA-DRB1 and HLA-DQB1 phenotypic frequencies were determined by direct count. Comparisons of HLA frequencies between patients and controls were performed using the Pearson χ^2 Test with continuity correction or the Fisher's

Table 1 Characteristics of TB patients and healthy controls

Parameter	TB patients (n = 92)
Age	
Mean \pm SD (years)	45,47 \pm 15,40
Range	21-82
Gender	
Female	33 (36%)
Male	59 (64%)
Positive TST	92 (100%)

TB patients and the HE group (data not shown). The HE group was stratified for the presence of HLA-DRB1*14 alleles. We found that the HLA-DRB1*14 allele was present in 0/6 cases (0% vs. 7% in the HE+ group (0/6 cases) (7% vs. 0; p = 0.008).

HLA-DQB1 alleles

There were no statistically significant differences in the frequencies of the distribution of HLA-DQB1 alleles between TB patients and the HE group.

The allele frequencies for normal HLA-DQB1 alleles were not substantially different from those found in the same region.²⁸

Discussion

TB pathogenesis is very complex and involves many factors influencing disease development and the outcome of infection. MT usually enters the body through the respiratory route. Phagocytosis of MT by macrophages is the first event in the process of interaction and may determine the

Table 2 HLA-DRB1* alleles phenotypic frequencies in TB patients and HE+ individuals

Alleles	TB patients (n = 92)	HE+ (n = 69)
HLA-DRB1*		

Within 2 to 6 weeks of infection, cell-mediated immunity is developed and an influx of lymphocytes and activated macrophages appears in the lesion, resulting in granuloma formation. The bacilli are contained in the granuloma, where they may remain forever (latent TB infection), or become re-activated at a later date to proliferate and ultimately evolve to an active disease state.

Not all individuals exposed to MT become infected. Of those who do become infected, the course and duration of progression to active disease are highly variable. This lack of uniformity in disease manifestation among infected individuals may reflect a complex interaction between genetic and environmental factors. The relative weight of some risk factors, such as AIDS, diabetes, family income and nutritional status, are known, but host genetic factors may also influence susceptibility to infection and disease pathogenesis. Despite the compelling rationale for the involvement of host genetic influences, evidence for a genetic basis for TB susceptibility has been difficult to establish.

Some candidate genes have been reported,¹⁵⁻¹⁸ and a role for HLA, which is important in the immune response, has been recognized. In particular, a number of studies have reported an association between HLA Class II alleles and TB, but these associations are not consistent across different populations¹⁵⁻¹⁸ and the results remain controversial. A study by Ruggiero et al showed an increase in HLA-DR4 frequency in an Italian population.²⁹ A significant increase in the frequency of HLA-DRB1*14 has been reported in Iranian patients,³⁰ an association that was confirmed by Matrashkin et al in a Russian population.³¹ A case-control study published by Dubaniewicz et al reported a strong association of HLA-DRB1*16 with TB in a Polish population.³² More recently, this group confirmed and extended these results using a "high resolution" method, showing a high frequency of the HLA-DRB1*1601 allele³³ and a low frequency of HLA-DQB1*0201 in Polish TB patients; this latter result suggests that the HLA-DQB1*0201 allele may be linked to TB resistance. A high frequency of the HLA-DQB1*0501 allele has been reported among North American Indian³⁴ and Mexican³⁵ TB patients, whereas the frequency of the HLA-DQB1*0502 was increased among TB patients in a Thai population.¹⁶ In a report from Cambodia, the HLA-DQB1*0503 allele was found to be associated with TB whereas the HLA-DQB1*0501 allele was not.¹⁵ These differences are likely attributable to the differing ethnic backgrounds of the studied populations, but it should be

There are two tests used in clinical practice to identify individuals with latent TB. These are the tuberculin skin test, and the interferon-gamma release assay (IGRA), which identify a memory of an adaptive immune response against mycobacterial antigens. At the time of this study, IGRAs were not widely available and we could not use it.

The sensitivity of the tuberculin skin test is reduced in individuals with immunosuppression, and treatment, but those were not studied. The choice of TST cutpoint influences the proportion of true TST reaction is a true positive diagnosis versus a false positive, often due to cross-reactivity with infection with nontuberculous mycobacteria or BCG vaccination. But on the other hand, false negative TST reactions are generally in the latent phase. All exposed group who tested positive had a TST of 15 mm which is very likely MT-induced.

We found that the HLA-DRB1*14 allele was more frequent among TB patients compared to healthy controls. HLA-DRB1*14 could be a susceptibility allele for TB. Although the difference is relatively small compared with previous reports from Iran and Russia, it was found to be increased among TB patients. Further studies of these observations will require further studies in larger groups of patients and healthy, TB-exposed individuals.

Conflict of interest

Authors state that they don't have a conflict of interest.

References

1. Dye C, Scheele S, Dolin P, et al. Control strategies for the burden of tuberculosis: estimated impact on mortality by country. WHO Global Strategy on Tuberculosis Project. JAMA. 1999;282:677-86.
2. Parrish NM, Dick JD, Bishai WR. Mycobacterium tuberculosis. Trends Microbiol. 2001;9:398-94.
3. Jepson A, Fowler A, Banya W, et al. Acquired immune responses to Mycobacterium tuberculosis: a study of twins in West Africa. J Clin Invest. 2001;107:3989-94.
4. Classen CN, Warren M, Richardson J. Interactions in the community: the role of the host in tuberculosis.

HLA class II alleles as markers of tuberculosis susceptibility and resistance

pulmonary tuberculosis: haplotype analysis with HLA-A, B and DR genes. *Tuberculosis (Edinb)*. 2001;81:335-41.

10. Scola L, Crivello A, Marino V, et al. IL-10 and TNF-alpha polymorphisms in a sample of Sicilian patients affected by tuberculosis: implication for ageing and life span expectancy. *Mech Ageing Dev*. 2003;124:569-72.
11. Oral HB, Budak F, Uzaslan EK, et al. Interleukin-10 (IL-10) gene polymorphism as a potential host susceptibility factor in tuberculosis. *Cytokine*. 2006;35:143-7.
12. Henao MI, Montes C, París SC, et al. Cytokine gene polymorphisms in Colombian patients with different clinical presentations of tuberculosis. *Tuberculosis (Edinb)*. 2006;86:11-9.
13. Wilkinson RJ, Patel P, Llewelyn M, et al. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. *J Exp Med*. 1999;189:1863-74.
14. Lombard Z, et al. Association of HLA-DR, -DQ, and vitamin D receptor alleles and haplotypes with tuberculosis in the Venda of South Africa. *Hum Immunol*. 2006;67:643-54.
15. Goldfeld AE, Delgado JC, Thim S, et al. Association of an HLA-DQ allele with clinical tuberculosis. *JAMA*. 1998;279:226-8.
16. Vejbaesya S, Chierakul N, Luangtrakool K, et al. Associations of HLA class II alleles with pulmonary tuberculosis in Thais. *Eur J Immunogenet*. 2002;29:431-4.
17. Ravikumar M, Dheenadhayalan V, Rajaram K, et al. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. *Tuber Lung Dis*. 1999;79:309-17.
18. Low AS, Azmy I, Sharaf N, et al. Association between two tumour necrosis factor intronic polymorphisms and HLA alleles. *Eur J Immunogenet*. 2002;29:31-4.
19. Amirzargar AA, Yalda A, Hajabolbaghi M, et al. The association of HLA-DRB, DQA1, DQB1 alleles and haplotype frequency in Iranian patients with pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 2004;8:1017-21.
20. Kim HS, Park MH, Song EY, et al. Association of HLA-DR and HLA-DQ genes with susceptibility to pulmonary tuberculosis in Koreans: preliminary evidence of associations with drug resistance, disease severity, and disease recurrence. *Hum Immunol*. 2005;66:1074-81.
21. Delgado JC, Baena A, Thim S, et al. Ethnic-specific genetic associations with pulmonary tuberculosis. *J Infect Dis*. 2002;186:1463-8.
22. Goldfeld AE. Genetic susceptibility to pulmonary tuberculosis in Cambodia. *Tuberculosis (Edinb)*. 2004;84:76-81.
23. Programa Nacional de Luta Contra a Tuberculose, Direção Geral da Saúde. Tuberculose: dados preliminares de 2008 [in Portuguese]. Available from: <http://www.dgs.pt>
24. EuroTB and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance

of tuberculosis in Europe. Report notified in 2006. Saint-Maurice, F. sanitaire; March 2008. Available from: http://www.who.int/csr/tb/2006/rapports/2006/full_report.pdf

25. Duarte R, Amado J, Lucas H, et al. Pulmonology. [Treatment of latent update of guidelines, 2006] [Article]. *Pneumol*. 2007;13:397-418.
26. Miller SA, Dykes DD, Polesky HF. A simple method for extracting DNA from human nucleated cells. *Res*. 1988;16:1215.
27. Olerup O, Aldener A, Fogdell A. HLA-DP PCR amplification with sequence-specific primers. *Tissue Antigens*. 1993;41:119-22.
28. Moraes A, Alves H, Lima B, et al. HLA class II gene polymorphisms in sarcoidosis patients. *Res*. 2008;14:727-46.
29. Ruggiero G, Consntini E, Zanzi D. HLA-DP human leucocyte antigen in historical tuberculosis patients in Southern Italy. *Res*. 2002;12:318-22.
30. Mahmoudzadeh-Niknam H, Khalilzadeh A. Distribution of human leukocyte antigen (HLA) class II alleles with pulmonary tuberculosis. *Hum Immunogenet*. 2002;29:431-4.
31. Matrashkin AG, Mes'ko EM, Pospelova N. Distribution of HLA antigens in patients with tuberculosis and in healthy individuals in the Erza District. *Tuberk*. 2002(12):15-6.
32. Cox RA, Downs M, Neimes RE, et al. HLA class II alleles in human tuberculosis. *J Infect Dis*. 1988;157:1074-81.
33. Dubaniewicz A, Moszkowska G, Szczepanik A. HLA-DRB1-DQB1 two-locus haplotypes in Polish patients. *Tuberculosis (Edinb)*. 2005;85:1017-21.
34. Rani R, Fernandez-Vina MA, Stastny A. HLA class II alleles in a North Indian population. *Res*. 1998;52:37-43.
35. Teran-Escandon D, Terán-Ortiz L, et al. Human leukocyte antigen-associated polymorphisms in pulmonary tuberculosis: molecular analysis by DNA amplification and oligonucleotide hybridization. *Chest*. 1999;115:428-33.
36. Reyn CF, Horsburgh CR, Olivier KN, et al. Sensitivity of *Mycobacterium tuberculosis* purified protein derivative (PPD-RT23) to *Mycobacterium avium* sensitization in medical students in the United States. *Chest*. 2001;120:1122-8.
37. Edwards LB, Acquaviva FA, Livesey JH. Tuberculosis infected: Dual tests and the future. *Rev Resp Dis*. 1977;108:1334-9.